Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

CONCLUSIONS
Faster aspart effectively improved HbA1c, and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp. Subjects randomized to postmeal faster aspart for all meals maintained HbA1c noninferior to that obtained with mealtime IAsp.

Source: Diabetes Care - June 21, 2017 Category: Endocrinology Authors: Russell-Jones, D.; Bode, B. W.; De Block, C.; Franek, E.; Heller, S. R.; Mathieu, C.; Philis-Tsimikas, A.; Rose, L.; Woo, V. C.; Osterskov, A. B.; Graungaard, T.; Bergenstal, R. M. Tags: Emerging Technologies and Therapeutics Source Type: research